electroCore, Inc.

As Chief Executive Officer, Daniel is responsible for leading and guiding the overall vision and goals of electroCore. Prior to joining the company, Daniel served as Executive Chairman of Repro Med Systems, Inc. (RMS), a publicly traded developer of home and specialty infusion products, and previously served as the company’s Chairman and interim Chief Executive Officer. He has over 35 years of leadership and medical device experience, including; Director and Chief Executive Officer of Xtant Medical Holdings, Inc. and Director and Chief Executive Officer of Sound Surgical Technologies. Earlier in his career, Daniel held various positions at Glucon, Inc., OSI Systems, Ohmeda, Nellcor and Hewlett Packard.

Daniel earned his B.S. in Mechanical Engineering from Massachusetts Institute of Technology, his M.S. in Mechanical Engineering from Stanford University and attended the Stanford Directors College.

Brian is a strategic and financial leader with more than 30 years of diversified management experience working in both public and private companies ranging from start-up to $1 billion.

Brian has served as Chief Financial Officer at several life science and emerging technology companies, including Cellectar Biosciences, Alliqua BioMedical, Ocean Power Technologies, and Power Medical Interventions. Earlier in his career, Brian spent nine years at Pharmacopeia, where he rose from Director of Finance to Chief Financial Officer before the company was acquired by Ligand Pharmaceuticals. Prior to Pharmacopeia, he was Chief Financial Officer and Vice President of Operations at Photosynthetic Harvest and Regional Chief Financial Officer at Omnicare. Brian began his career as an audit supervisor at Coopers & Lybrand, which was subsequently merged to form PricewaterhouseCoopers.

Brian earned his MBA in managerial accounting from Pace University and his Bachelor of Arts in accounting from Queens College.

As electroCore’s Chief Medical Officer, Dr. Peter Staats is responsible for overseeing the ongoing clinical development of gammaCore™ and works to advance the technology into new potential indications. Dr. Staats is a co-founder of electroCore and has previously served on the board of directors. He was the founder of the Division of Pain Medicine at Johns Hopkins University, where he was the director for 10 years. Dr. Staats is internationally recognized for his work in developing neuromodulation strategies and for implementing minimally invasive procedures for chronic pain.

Dr. Staats received his medical degree from the University of Michigan Medical School in Ann Arbor and completed his residency and fellowship training at the Johns Hopkins University School of Medicine. He is a past President of the North American Neuromodulation Society, American Society of Interventional Pain Physicians, New Jersey Society of Interventional Pain Physicians, and the Southern Pain Society. He is currently President Elect of the World Institute of Pain and continues to serve as Chief Medical Officer for National Spine and Pain Centers, the largest pain practice in the United States.

Dr. Staats has written or co-edited 11 books and over 400 articles, abstracts, monographs, and book chapters on pain medicine in publications that include the Journal of the American Medicine Association, Pain, Anesthesiology, Lancet Neurology and the Journal of Clinical Oncology. His work has been highlighted on Good Morning America, CBS Evening News, Newsweek, and CNN. He has lectured extensively nationally and internationally. He has received numerous awards including both the physician of the year and the lifetime achievement awards from the New York, New Jersey, and West Virginia branches of the American Society of Interventional Pain Physicians; Best Doctors in America, Top Doctors, and New Jersey Top Doctor; and the lifetime achievement awards from the American Society of Interventional Pain Physicians and the North American Neuromodulation society.

Mr. Lev has been the Chief Strategy Officer since January 2022. He joined electroCore in February 2020 as the VP of Business Development, Strategy and Financial Planning. Mr. Lev has over 15 years experience in the financial services industry including 10+ years spent as an investment banker and investor focusing on emerging growth companies. Joshua joined Wellfleet Partners, Inc., as the Director of Business Development in mid-2011 to focus on capital raises, M&A, strategic transactions and institutional client relations. Later in his career, he helped co-found Aracle Capital, LLC., an investment firm with a focus on early-stage and emerging-growth companies. Over the span of his career, Mr. Lev has been involved in the financial and strategic planning of companies across multiple sizes and industries.

Mr. Lev holds an MBA from the University of North Carolina’s Kenan-Flagler Business School where he graduated with a concentration in finance and as a member of both the Dean’s List and Beta Gamma Sigma Honor Society. He also holds a Bachelor of Science in Business & Management from the Sy Syms School of Business at Yeshiva University, as well as an Associate Degree in Religious Studies.